細胞表面マーカーの世界市場予測(~2023年)

◆英語タイトル:Cell Surface Markers Market by Product (Antibody, PCR Array), Source (Mice, Rat), Cell Type (T cells, B cells, NK cell), Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology)), and End User (Hospitals) - Global Forecast to 2023
◆商品コード:BT 6815
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2018年12月18日
◆ページ数:141
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

細胞表面マーカーの世界市場は、2018年の5億2,000万ドルから2023年には7億6,900万ドルに達し、この期間中8.1%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、主にがんの世界的な罹患率の上昇、ライフサイエンス研究への資金提供の増加、そして幹細胞研究および神経生物学研究の伸びが考えられます。一方で、抗体開発プロセスに費用および時間がかかることにより、市場の成長が抑制される可能性があります。当調査レポートでは、細胞表面マーカーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品(抗体、PCRアレイ)分析、ソース(マウス、ラット)分析、細胞の種類(T細胞、B細胞、NK細胞)分析、用途(研究、臨床)分析、細胞表面マーカーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

“High global prevalence of cancer is expected to drive the overall growth of the cell surface markers market”The cell surface markers market is projected to reach USD 769 million by 2023 from USD 520 million in 2018, at a CAGR of 8.1% during the forecast period. The growth of this market is majorly driven by the high global prevalence of cancer, increasing funding for life sciences research, and growth in stem cell and neurobiology research. On the other hand, factors such as the costly and time-intensive antibody development process may hinder the growth of this market in the coming years.

“Antibodies segment is expected to grow at the highest CAGR during the forecast period”
Based on product type, the cell surface markers market is segmented into antibodies and PCR arrays. The antibodies segment is expected to account for a larger share of the market in 2018 as well as grow at a higher CAGR during the forecast period. This can majorly be attributed to the increasing demand for accurate and reliable antibodies by research communities.

“T cell surface markers segment is expected to account for the largest share of the cell surface markers market, by cell type, during the forecast period”
Based on cell type, the cell surface markers market is segmented into T cell surface markers, B cell surface markers, NK cell surface markers, monocyte cell surface markers, and other cell types. In 2018, the T cell surface markers segment is expected to account for the largest share of the cell surface markers market. The large share of this segment is attributed to the high and growing use of T cell surface markers in research and diagnostics.

“North America to dominate the market during the forecast period”
In 2018, North America is expected to account for the largest share of the cell surface markers market. North America has a well-established pharmaceuticals sector and currently dominates the cell surface markers market due to the increasing demand for the effective diagnosis and treatment of chronic diseases. Also, the adoption rate of cell surface markers for disease diagnostics, majorly for cancer diagnosis, is high in North America. This is one of the major factors supporting the growth of this regional market. The Asian market, on the other hand, is expected to grow at the highest CAGR during the forecast period. Factors such as government initiatives to boost biotechnology and pharmaceutical industries and increasing life sciences research activities are supporting the growth of the cell surface markers market in Asia.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 55%, Tier 2: 20%, Tier 3: 25%
• By Designation – C-level: 58%, D-level: 19%, Others: 23%
• By Region – North America: 40%, Europe: 30%, Asia: 10%, RoW: 20%

List of Companies Profiled in the Report
• Thermo Fisher Scientific (US)
• QIAGEN N.V. (Netherlands)
• Becton, Dickinson and Company (US)
• F. Hoffman-La Roche (Switzerland)
• Bio-Rad Laboratories (US)
• Danaher Corporation (US)
• Abcam (UK)
• Genscript (China)
• Biolegend (US)
• B. Braun Melsungen AG (Germany)
• Cell Signaling Technology (US)
• Merck KGaA (Germany)
• Bio-Techne (US)

Research Coverage:
This report provides a detailed picture of the global cell surface markers market. It aims at estimating the size and future growth potential of the market across different segments, such as product type, antibodies by source, cell type, application, end user, and region. The report also includes an in-depth competitive analysis of key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them the closest approximations of the revenue numbers for the overall cell surface markers market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKET COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DESIGN 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Key data from primary sources 21
2.2 MARKET SIZE ESTIMATION 22
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.4 ASSUMPTIONS FOR THE STUDY 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 30
4.1 CELL SURFACE MARKERS: MARKET OVERVIEW 30
4.2 CELL SURFACE MARKERS MARKET, BY PRODUCT 31
4.3 CELL SURFACE MARKERS MARKET, BY CELL TYPE (2018) 32
4.4 CELL SURFACE MARKERS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION) 33
4.5 CELL SURFACE MARKERS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION) 33
4.6 CELL SURFACE MARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 34
5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Increasing funding for life science research 36
5.2.1.2 High global prevalence of cancer 36
5.2.1.3 Growth in stem cell and neurobiology research 37
5.2.2 RESTRAINTS 38
5.2.2.1 Costly and time-intensive antibody development process 38
5.2.3 OPPORTUNITIES 38
5.2.3.1 High growth opportunities in emerging markets 38
6 CELL SURFACE MARKERS MARKET, BY PRODUCT 39
6.1 INTRODUCTION 40
6.2 ANTIBODIES 41
6.2.1 ANTIBODIES TO DOMINATE THE CELL SURFACE MARKER PRODUCTS MARKET DURING THE FORECAST PERIOD 41
6.3 PCR ARRAYS 41
6.3.1 PCR ARRAY PROFILES THE EXPRESSION OF GENES RELEVANT TO RESEARCH AT THE CELL SURFACE MARKER LEVEL 41
7 CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE 43
7.1 INTRODUCTION 44
7.2 MICE 45
7.2.1 MICE ARE THE MOST PREFERRED HOSTS FOR RESEARCH-USE CELL SURFACE ANTIBODY PRODUCTION 45
7.3 RATS 45
7.3.1 RATS ARE THE SECOND-MOST-WIDELY USED ANIMAL HOSTS FOR MONOCLONAL ANTIBODY PRODUCTION 45
7.4 OTHER SOURCES 46
8 CELL SURFACE MARKERS MARKET, BY CELL TYPE 47
8.1 INTRODUCTION 48
8.2 T CELL SURFACE MARKERS 49
8.2.1 T CELL SURFACE MARKERS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018 49
8.3 B CELL SURFACE MARKERS 49
8.3.1 B CELL SURFACE MARKERS ARE USED TO IDENTIFY B CELLS FROM HETEROGENEOUS SAMPLES 49
8.4 NK CELL SURFACE MARKERS 50
8.4.1 NK CELL SURFACE MARKERS IDENTIFY NK CELLS AT VARIOUS STAGES OF DEVELOPMENT 50
8.5 MONOCYTE CELL SURFACE MARKERS 51
8.5.1 MONOCYTES PLAY A CRITICAL ROLE IN MAINTAINING OVERALL HEALTH 51
8.6 OTHER CELL TYPES 51
9 CELL SURFACE MARKERS MARKET, BY APPLICATION 53
9.1 INTRODUCTION 54
9.2 RESEARCH APPLICATIONS 55
9.2.1 DRUG DISCOVERY 56
9.2.1.1 Cell surface markers play an important role in guiding decisions in every phase of drug development 56

9.2.2 IMMUNOLOGY 57
9.2.2.1 The assessment of cell surface antigens using cell surface markers is an important field of immunological research 57
9.2.3 STEM CELL RESEARCH 57
9.2.3.1 Cell surface biomarkers are used to characterize, isolate, and analyze stem cells 57
9.2.4 OTHER RESEARCH APPLICATIONS 58
9.3 CLINICAL APPLICATIONS 59
9.3.1 ONCOLOGY 60
9.3.1.1 Cell surface markers are an emerging diagnostic tool in the field of hematological oncology. 60
9.3.2 IMMUNODEFICIENCY DISEASES 60
9.3.2.1 Cell surface markers are used for the detection of HIV infections 60
9.3.3 OTHER CLINICAL APPLICATIONS 61
10 CELL SURFACE MARKERS MARKET, BY END USER 62
10.1 INTRODUCTION 63
10.2 ACADEMIC & RESEARCH INSTITUTES 64
10.2.1 ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS OF THE CELL SURFACE MARKERS MARKET 64
10.3 HOSPITALS & CLINICAL TESTING LABORATORIES 65
10.3.1 HOSPITALS & CLINICAL TESTING LABORATORIES USE CELL SURFACE MARKERS FOR THE DIAGNOSIS OF VARIOUS DISEASES 65
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 65
10.4.1 PATENT EXPIRATION OF BLOCKBUSTER DRUGS TO DRIVE THE GROWTH OF THE CELL MARKERS MARKET FOR THIS END-USER SEGMENT 65
11 CELL SURFACE MARKERS MARKET, BY REGION 67
11.1 INTRODUCTION 68
11.2 NORTH AMERICA 69
11.2.1 US 73
11.2.1.1 High prevalence of chronic diseases 73
11.2.1.2 Favorable funding for precision medicine research activities 73
11.2.2 CANADA 76
11.2.2.1 Availability of research funding 76
11.2.2.2 Increasing prevalence of cancer 76
11.3 EUROPE 79
11.3.1 GERMANY 83
11.3.1.1 Availability of funding driving the number of research activities 83
11.3.1.2 Large-scale outsourcing of clinical diagnostic testing by hospitals to commercial service providers 83
11.3.2 FRANCE 85
11.3.2.1 Presence of a large biotechnology industry 85
11.3.2.2 Government initiatives to boost research and development activities 85
11.3.3 UK 87
11.3.3.1 Government initiatives to strengthen academic research 87
11.3.3.2 Increasing incidence and prevalence of chronic and infectious diseases 88
11.3.4 ROE 90
11.4 ASIA 93
11.5 ROW 98
12 COMPETITIVE LANDSCAPE 103
12.1 OVERVIEW 103
12.2 MARKET RANKING ANALYSIS 104
12.3 COMPETITIVE SCENARIO 105
12.3.1 PARTNERSHIPS AND AGREEMENTS (2016–2018) 105
12.3.2 PRODUCT LAUNCHES (2016–2018) 106
12.3.3 ACQUISITIONS (2016–2018) 106
12.3.4 EXPANSIONS (2016–2018) 106
13 COMPANY PROFILES 108
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 THERMO FISHER SCIENTIFIC 108
13.2 BECTON, DICKINSON AND COMPANY 111
13.3 ABCAM 113
13.4 QIAGEN N.V. 115
13.5 F. HOFFMAN-LA ROCHE 118
13.6 BIO-RAD LABORATORIES 120
13.7 DANAHER CORPORATION 122
13.8 GENSCRIPT 124
13.9 BIOLEGEND 126
13.10 CELL SIGNALING TECHNOLOGY 128
13.11 BIO-TECHNE 129
13.12 MERK KGAA 131

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX 134
14.1 DISCUSSION GUIDE 134
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 137
14.3 AVAILABLE CUSTOMIZATIONS 139
14.4 RELATED REPORTS 139
14.5 AUTHOR DETAILS 140

LIST OF TABLES

TABLE 1 GLOBAL CANCER INCIDENCE, 2018 VS. 2025 37
TABLE 2 CELL SURFACE MARKERS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 40
TABLE 3 CELL SURFACE MARKER ANTIBODIES MARKET, BY REGION,
2016–2023 (USD MILLION) 41
TABLE 4 CELL SURFACE MARKER PCR ARRAYS MARKET, BY REGION,
2016–2023 (USD MILLION) 42
TABLE 5 CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 44
TABLE 6 CELL SURFACE MARKER ANTIBODIES MARKET FOR MICE, BY REGION,
2016–2023 (USD MILLION) 45
TABLE 7 CELL SURFACE MARKER ANTIBODIES MARKET FOR RATS, BY REGION,
2016–2023 (USD MILLION) 46
TABLE 8 CELL SURFACE MARKER ANTIBODIES MARKET FOR OTHER SOURCES,
BY REGION, 2016–2023 (USD MILLION) 46
TABLE 9 CELL SURFACE MARKERS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION) 48
TABLE 10 T CELL SURFACE MARKERS MARKET, BY REGION, 2016–2023 (USD MILLION) 49
TABLE 11 B CELL SURFACE MARKERS MARKET, BY REGION, 2016–2023 (USD MILLION) 50
TABLE 12 NK CELL SURFACE MARKERS MARKET, BY REGION, 2016–2023 (USD MILLION) 50
TABLE 13 MONOCYTE CELL SURFACE MARKERS MARKET, BY REGION,
2016–2023 (USD MILLION) 51
TABLE 14 CELL SURFACE MARKERS MARKET FOR OTHER CELL TYPES,
BY REGION, 2016–2023 (USD MILLION) 52
TABLE 15 CELL SURFACE MARKERS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 54
TABLE 16 CELL SURFACE MARKERS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 55
TABLE 17 CELL SURFACE MARKERS MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2016–2023 (USD MILLION) 55
TABLE 18 CELL SURFACE MARKERS MARKET FOR DRUG DISCOVERY, BY REGION,
2016–2023 (USD MILLION) 56
TABLE 19 CELL SURFACE MARKERS MARKET FOR IMMUNOLOGY, BY REGION,
2016–2023 (USD MILLION) 57
TABLE 20 CELL SURFACE MARKERS MARKET FOR STEM CELL RESEARCH,
BY REGION, 2016–2023 (USD MILLION) 58
TABLE 21 CELL SURFACE MARKERS MARKET FOR OTHER RESEARCH APPLICATIONS,
BY REGION, 2016–2023 (USD MILLION) 58
TABLE 22 CELL SURFACE MARKERS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 59
TABLE 23 CELL SURFACE MARKERS MARKET FOR CLINICAL APPLICATIONS,
BY REGION, 2016–2023 (USD MILLION) 59
TABLE 24 CELL SURFACE MARKERS MARKET FOR ONCOLOGY, BY REGION,
2016–2023 (USD MILLION) 60
TABLE 25 CELL SURFACE MARKERS MARKET FOR IMMUNODEFICIENCY DISEASES,
BY REGION, 2016–2023 (USD MILLION) 61
TABLE 26 CELL SURFACE MARKERS MARKET FOR OTHER CLINICAL APPLICATIONS,
BY REGION, 2016–2023 (USD MILLION) 61
TABLE 27 CELL SURFACE MARKERS MARKET, BY END USER, 2016–2023 (USD MILLION) 63
TABLE 28 CELL SURFACE MARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2016–2023 (USD MILLION) 64
TABLE 29 CELL SURFACE MARKERS MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY REGION, 2016–2023 (USD MILLION) 65
TABLE 30 CELL SURFACE MARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2016–2023 (USD MILLION) 66
TABLE 31 CELL SURFACE MARKERS MARKET, BY REGION, 2016–2023 (USD MILLION) 68
TABLE 32 NORTH AMERICA: CELL SURFACE MARKERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 70
TABLE 33 NORTH AMERICA: CELL SURFACE MARKERS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 70
TABLE 34 NORTH AMERICA: CELL SURFACE MARKER ANTIBODIES MARKET,
BY SOURCE, 2016–2023 (USD MILLION) 70
TABLE 35 NORTH AMERICA: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 71
TABLE 36 NORTH AMERICA: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 71
TABLE 37 NORTH AMERICA: CELL SURFACE MARKERS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2016–2023 (USD MILLION) 71
TABLE 38 NORTH AMERICA: CELL SURFACE MARKERS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2016–2023 (USD MILLION) 72
TABLE 39 NORTH AMERICA: CELL SURFACE MARKERS MARKET, BY END USER,
2016–2023 (USD MILLION) 72
TABLE 40 US: CELL SURFACE MARKERS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 74
TABLE 41 US: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 74
TABLE 42 US: CELL SURFACE MARKERS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION) 74
TABLE 43 US: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 75
TABLE 44 US: CELL SURFACE MARKERS MARKET, BY END USER, 2016–2023 (USD MILLION) 75
TABLE 45 CANADA: CELL SURFACE MARKERS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 76
TABLE 46 CANADA: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 77
TABLE 47 CANADA: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 77
TABLE 48 CANADA: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 78
TABLE 49 CANADA: CELL SURFACE MARKERS MARKET, BY END USER,
2016–2023 (USD MILLION) 78
TABLE 50 EUROPE: CELL SURFACE MARKERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 80
TABLE 51 EUROPE: CELL SURFACE MARKERS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 80
TABLE 52 EUROPE: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 80
TABLE 53 EUROPE: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 81
TABLE 54 EUROPE: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 81
TABLE 55 EUROPE: CELL SURFACE MARKERS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 82
TABLE 56 EUROPE: CELL SURFACE MARKERS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 82
TABLE 57 EUROPE: CELL SURFACE MARKERS MARKET, BY END USER,
2016–2023 (USD MILLION) 82
TABLE 58 GERMANY: CELL SURFACE MARKERS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 83
TABLE 59 GERMANY: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 84
TABLE 60 GERMANY: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 84
TABLE 61 GERMANY: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 84
TABLE 62 GERMANY: CELL SURFACE MARKERS MARKET, BY END USER,
2016–2023 (USD MILLION) 85
TABLE 63 FRANCE: CELL SURFACE MARKERS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 86
TABLE 64 FRANCE: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 86
TABLE 65 FRANCE: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 86
TABLE 66 FRANCE: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 87
TABLE 67 FRANCE: CELL SURFACE MARKERS MARKET, BY END USER,
2016–2023 (USD MILLION) 87
TABLE 68 UK: CELL SURFACE MARKERS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 88
TABLE 69 UK: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 88
TABLE 70 UK: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 89
TABLE 71 UK: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 89
TABLE 72 UK: CELL SURFACE MARKERS MARKET, BY END USER, 2016–2023 (USD MILLION) 90
TABLE 73 ROE: CELL SURFACE MARKERS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 91
TABLE 74 ROE: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 91
TABLE 75 ROE: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 91
TABLE 76 ROE: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 92
TABLE 77 ROE: CELL SURFACE MARKERS MARKET, BY END USER,
2016–2023 (USD MILLION) 92
TABLE 78 ASIA: CELL SURFACE MARKERS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 95
TABLE 79 ASIA: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 95
TABLE 80 ASIA: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 95
TABLE 81 ASIA: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 96
TABLE 82 ASIA: CELL SURFACE MARKERS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 96
TABLE 83 ASIA: CELL SURFACE MARKERS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 97
TABLE 84 ASIA: CELL SURFACE MARKERS MARKET, BY END USER,
2016–2023 (USD MILLION) 97
TABLE 85 ROW: CELL SURFACE MARKERS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 100
TABLE 86 ROW: CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION) 100
TABLE 87 ROW: CELL SURFACE MARKERS MARKET, BY CELL TYPE,
2016–2023 (USD MILLION) 100
TABLE 88 ROW: CELL SURFACE MARKERS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 101
TABLE 89 ROW: CELL SURFACE MARKERS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 101
TABLE 90 ROW: CELL SURFACE MARKERS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2016–2023 (USD MILLION) 102
TABLE 91 ROW: CELL SURFACE MARKERS MARKET, BY END USER,
2016–2023 (USD MILLION) 102


LIST OF FIGURES

FIGURE 1 CELL SURFACE MARKER MARKET SEGMENTATION 17
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 22
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 23
FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 23
FIGURE 5 DATA TRIANGULATION METHODOLOGY 24
FIGURE 6 CELL SURFACE MARKERS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION) 26
FIGURE 7 CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE 27
FIGURE 8 CELL SURFACE MARKERS MARKET, BY CELL TYPE, 2018 VS. 2023 (USD MILLION) 27
FIGURE 9 CELL SURFACE MARKERS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION) 28
FIGURE 10 CELL SURFACE MARKERS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION) 28
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CELL SURFACE MARKERS MARKET 29
FIGURE 12 HIGH GLOBAL BURDEN OF CANCER & INCREASING FUNDING FOR LIFE SCIENCE RESEARCH ARE DRIVING THE GROWTH OF THE CELL SURFACE MARKERS MARKET 30
FIGURE 13 ANTIBODIES SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 31
FIGURE 14 T CELL SURFACE MARKERS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018 32
FIGURE 15 CLINICAL APPLICATIONS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 33
FIGURE 16 ACADEMIC & RESEARCH INSTITUTES SEGMENT TO DOMINATE THE CELL SURFACE MARKERS MARKET DURING THE FORECAST PERIOD 33
FIGURE 17 ASIA IS THE FASTEST-GROWING REGION IN THE CELL SURFACE MARKERS MARKET 34
FIGURE 18 CELL SURFACE MARKERS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 35
FIGURE 19 ANTIBODIES SEGMENT WILL CONTINUE TO DOMINATE THE CELL SURFACE MARKER PRODUCTS MARKET DURING THE FORECAST PERIOD 40
FIGURE 20 MICE SEGMENT TO WITNESS THE HIGHEST GROWTH IN THE CELL SURFACE MARKER ANTIBODIES MARKET DURING THE FORECAST PERIOD 44
FIGURE 21 T CELL SURFACE MARKERS SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 48
FIGURE 22 RESEARCH APPLICATIONS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE CELL SURFACE MARKERS MARKET IN 2018 54
FIGURE 23 HOSPITALS & CLINICAL TESTING LABORATORIES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 63
FIGURE 24 NORTH AMERICA: CELL SURFACE MARKERS MARKET SNAPSHOT 69
FIGURE 25 EUROPE: CELL SURFACE MARKERS MARKET SNAPSHOT 79
FIGURE 26 ASIA: CELL SURFACE MARKERS MARKET SNAPSHOT 94
FIGURE 27 ROW: CELL SURFACE MARKERS MARKET SNAPSHOT 99
FIGURE 28 KEY DEVELOPMENTS IN THE CELL SURFACE MARKERS MARKET
(JAN 2016-NOV 2018) 103
FIGURE 29 MARKET EVOLUTION FRAMEWORK 104
FIGURE 30 CELL SURFACE MARKERS MARKET RANKING ANALYSIS, BY KEY PLAYER (2017) 104
FIGURE 31 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC (2017) 108
FIGURE 32 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2017) 111
FIGURE 33 COMPANY SNAPSHOT: ABCAM (2018*) 113
FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2017) 115
FIGURE 35 COMPANY SNAPSHOT: F. HOFFMANN-LA ROCHE AG (2017) 118
FIGURE 36 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2017) 120
FIGURE 37 COMPANY SNAPSHOT: DANAHER CORPORATION (2017) 122
FIGURE 38 COMPANY SNAPSHOT: GENSCRIPT (2017) 124
FIGURE 39 COMPANY SNAPSHOT: BIO-TECHNE (2017) 129
FIGURE 40 COMPANY SNAPSHOT: MERCK KGAA (2017) 131


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[細胞表面マーカーの世界市場予測(~2023年)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆